Therefore, we wanted to test if the CAMKK2-AMPK pathway could be the first pathway identified to coherently regulate the major AD phenotypes, and, more precisely, if Aβ42o-dependent overactivation of AMPK triggers synaptic loss through its ability to mediate mitochondrial structural remodeling. The gene discussed is PRKAA1; the disease is Alzheimer disease.